Phase 2 Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 to 75 years old.
- People whose general health and ability to carry out daily activities is rated at a good level (score of 0 or 1 on a standard oncology scale).
- People expected to live for at least 12 weeks.
- People who have at least one measurable tumour lesion, based on standard imaging measurement criteria.
- People who have previously been treated with certain chemotherapy drug types (taxanes and/or anthracyclines) at any point during their breast cancer treatment.
- People whose breast cancer has tested negative for the HER2 protein, confirmed through standard laboratory tests.
- People who have received at least one round of chemotherapy for advanced (metastatic or late-stage) breast cancer.
- People whose blood test results meet specific requirements for immune cell levels, platelet counts, and haemoglobin levels (confirm with trial site for exact values).
- People whose liver function blood tests fall within acceptable ranges, with slightly higher limits allowed for those with liver metastases (confirm with trial site for exact values).
- People whose kidney function tests fall within acceptable ranges (confirm with trial site for exact values).
- People whose heart pumping function, measured by an echocardiogram, is at or above 50%.
- People whose heart rhythm, measured by an ECG, falls within acceptable limits for their sex (confirm with trial site for exact values).
- People who are willing to participate voluntarily, sign a consent form, and attend follow-up appointments.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a significant build-up of fluid in body cavities (such as the chest or abdomen) that cannot be controlled by drainage or other treatments.
- People who have brain or nervous system metastases that are causing symptoms or are not under control.
- People whose only assessable areas of cancer spread are in the bones or skin.
- People who have previously had another type of cancer.
- People who have already been treated with the drug Eribulin during their advanced stage of disease.
- People with a known allergy to any components of the trial treatments, a history of immune system deficiency (including HIV positive status), other immune disorders present from birth or developed over time, or a history of organ transplantation.
- People with any heart condition, or any other condition that the treating doctor considers unsuitable for participation.
- People who are pregnant or breastfeeding, people of childbearing potential who test positive on a pregnancy test at the start of the trial, or people of reproductive age who are unwilling to use effective contraception throughout the trial.
- People who have other existing medical conditions that the doctor believes could seriously affect their safety or ability to complete the study — examples include severe bleeding tendencies, recent surgery within the past two weeks, high blood pressure that cannot be managed with medication, serious diabetes, active infection, or thyroid disease.
- People with a known history of neurological or mental health conditions, including epilepsy or dementia.
- People whose cancer did not show signs of getting worse on their most recent anti-cancer treatment before joining the trial, based on standard imaging criteria.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jiayu Wang, doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phone: +86-15600990767
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.